OvaSure Guidance, June 4, 2009

The Society of Gynecologic Oncologists has issued a position statement on a new ovarian cancer screening test called OvaSure™. The Foundation for Women’s Cancer is sharing this statement with you as a Guidance to Women.

We all share the goal of early detection of ovarian cancer, but the OvaSure™ test has not undergone the rigorous clinical trials testing needed to demonstrate its safety and efficacy. For a screening test such as this to be considered effective, a clinical trial must demonstrate a reduction in deaths from ovarian cancer in a population of women evaluated with the test.

You might ask what is the harm in endorsing any test that might help reduce deaths from ovarian cancer? The potential harm comes from several possible problems including: 1) false reassurance from a negative test; 2) the possibility of unnecessary surgeries; and 3) the significant stress and anxiety that may come from a false positive test.

We all look forward to the day when a proven screening test is available, unfortunately we aren’t there yet. Please distribute this attached SGO statement as you feel appropriate.

Spotlight

Visit the Sisterhood of Survivorship page to read “Dena’s Story” — by a vulvar cancer survivor who has shared her story and wise words, and channeled her energy into her National Race to End Women’s Cancer team.

Awareness

The CDC recently announced that fewer than half of American children are given the HPV vaccination.

Research

As of the July 23 deadline, 55 research abstracts were submitted in hopes of receiving one of only 6 grants from the Foundation. This points to a need for more funding so that the Foundation may award grants to every deserving applicant.

Education

The Gynecologic Cancer Global Health Forum will be Saturday, Sept. 6, 2014 in D.C.. For more information on educational events and courses, click here.